PBS Calendars

Page last updated: 29 April 2016

PBS related activities surrounding the 2016 to 2018 PBAC meeting cycles

If you are considering applying to have a drug listed on the PBS, it is recommended that you contact the Pharmaceutical Evaluation Branch to discuss the listing steps. If you are unsure of the most appropriate person to contact, the Industry Liaison Officer will be able to assist.

All contact details are available from the PBS contacts page.

PBAC Cycle Timeframe for 2016 - 2018

PBAC Cycle Timeframes

MEETING

2016/1

9-11 March

2016/2

6-8 July

2016/3

2-4 November

2017/1

8-10 March

Activity

Wk

Date

Wk

Date

Wk

Date

Wk

Date

(PBAC meeting Wed-Friday)

Deadline for major submissions (Wednesday)

 

0

 

4 Nov 2015

 

0

 

9 March 2016

 

0

 

6 July 2016

 

0

 

2 Nov 2016

 

1

 

1

 

1

 

1

 

 

2

 

2

 

2

 

2

 

 

3

 

3

 

3

 

3

 

 

4

 

4

 

4

 

4

 

Submissions to discussants (Wednesday)

 

Pre submission meetings with companies (future submissions only)

5

7 Dec 2015 – 8 Jan 2016
(25,28 Dec/1 Jan PH)

5

11 Apr – 6 May 2016
(25 Apr PH)

5

10 Aug 2016

 

8 Aug – 2 Sept 2016

5

7 Dec 2016



5 Dec 2016 – 6 Jan 2017
(26-27 Dec, 2 Jan PH)

Deadline for minor submissions (including Secretariat listings) (Friday)

6

18 Dec 2015

6

22 Apr 2016

6

19 Aug 2016

6

16 Dec 2016

Publication of PBAC agenda on PBS website (Wednesday)

7

23 Dec 2015

7

28 Apr 2016

7

24 Aug 2016

7

21 Dec 2016

 

8

 

8

 

8

 

8

 

 

9

 

9

 

9

 

9

 

Major submission commentaries to “Responsible Persons”

10

20 Jan 2016

10

18 May 2016

10

14 Sept 2016

10

18 January 2017

“Responsible Persons” send Pre-Subcommittee Responses to PBAC Secretariat (by midday Wednesday)

 

Pre submission meetings with companies (future submissions only)

11

27 Jan 2016

 

 

25-29 Jan 2016 (26 Jan PH)

11

25 May 2016

 

 

23-27 May 2016

11

21 Sept 2016

 

 

19-23 Sept 2016

11

25 January 2017

 

 

23-27 Jan 2017
(26 Jan PH)

DUSC meeting (Thursday-Friday)

 

12

4-5 Feb 2016

12

2-3 June 2016

12

29-30 Sept 2016

12

2-3 Feb 2017

ESC meeting (Monday-Tuesday)

 

Closing date for online consumer comments

13

8-9 Feb 2016

 

10 Feb 2016

13

6-7 June 2016

 

8 June 2016

13

4-5 Oct 2016
(3 Oct PH)


5 October 2016

13

6-7 Feb 2017
 


8 February 2016

ATAGI meeting (Thursday – Friday)

14

18-19 Feb 2016

14

16-17 June 2016

14

13-14 Oct 2016

14

16-17 Feb 2017

Minor submission overviews, ESC (major submissions only), DUSC (selected major submissions only), & ATAGI (vaccine submissions only) advice & summary of consumer comments to “Responsible Persons” (Wednesday)

15

24 Feb 2016

15

22 June 2016

15

19 Oct 2016

15

22 Feb 2017

“Responsible Persons” send Pre-PBAC Responses to PBAC Secretariat (by midday Wednesday)

 

Pre submission meetings with companies not relating to imminent submissions(future submissions only)

16

2 March 2016

 

29 Feb – 4 Mar 2016

16

29 June 2016

 

27 Jun – 1 July 2016

16

26 Oct 2016

 

24-28 Oct 2016

16

1 March 2017

 

27 Mar-3 Feb 2017

PBAC meeting Wednesday-Friday

 

(Close for major submissions on Wednesday)

17

9-11 Mar 2016

 

9 Mar 2016

17

6-8 July 2016

 

6 July 2016

17

2-4 Nov 2016

 

2 Nov 2016

17

8-10 Mar 2017

 

8 Mar 2017

POST PBAC PROCEDURES:

18

 

18

 

18

 

18

 

 

19

 

19

 

19

 

19

 

Ratified Minutes (positive recommendations) to “Responsible Persons” (Friday)

20

1 April 2016

20

29 July 2016

20

25 Nov 2016

20

31 Mar 2017

 

21

 

21

 

21

 

21

 

Ratified Minutes (all other recommendations) to “Responsible Persons” (Friday)

22

15 April 2016

22

12 Aug 2016

22

9 Dec 2016

22

13 Apr 2017
(14 Apr PH)

Posting of recommendations on website following sponsor’s comments*

23

22 April 2016

23

19 Aug 2016

23

16 Dec 2016

23

21 Apr 2017

Deadline for Independent Review requests for reconsideration at the meeting following the next meeting

24

29  April 2016

24

26 August 2016

24

23 Dec 2016

24

28 Apr 2017

 

25

 

25

 

25

 

25

 

 

26

 

26

 

26

 

26

 

Draft PSDs  to “Responsible Persons”

27

20 May 2016

27

16 Sept 2016

27

20 Jan 2017

27

19 May 2017

 

28

 

28

 

28

 

28

 

 

29

 

29

 

29

 

29

 

 

30

 

30

 

30

 

30

 

 

31

 

31

 

31

 

31

 

Finalisation of PSDs (Friday)

32

24 June 2016

32

21 Oct 2016

32

24 Feb 2017

32

23 Jun 2017

PSDs published on web site (positives & subsequent rejections)

33

1 July 2016

33

28 Oct 2016

33

3 March 2017

33

30 Jun 2017

 

0

 

0

 

0

 

0

 

PSDs published on web site (1st time rejections & deferrals)

1

15 July 2016

1

11 Nov 2016

1

17 March 2017

1

14 Jul 2017

PBAC = Pharmaceutical Benefits Advisory Committee
“responsible persons” = legal wording requirement for terminology – previously known as sponsors
DUSC = Drug Utilisation Sub Committee    
ESC = Economic Sub Committee
ATAGI = Australian Technical Advisory Group on Immunisation
PSDs = Public Summary Documents
TBC = To be Confirmed
    
*  These dates may vary based on the number of submissions received    

Accessibility

The documents on this page may not be accessible. If you need help please contact HTA compliance (secretariat.compliance@health.gov.au).

Suitable Dates for Sponsors to meet with the Pharmaceutical Evaluation Branch (PEB)

It is quite routine for sponsors to meet with relevant officers in the PEB prior to submitting to the PBAC, however, the available opportunities for these meetings is limited by busy periods within the PBAC meeting cycle when key personnel have other priorities.

The weeks in the cycles assigned for PEB-Sponsor meetings can be found in the PBAC Cycle Timeframe Calendar.

Please complete and return the meeting request form (Word 23 KB) to HTA compliance (secretariat.compliance@health.gov.au).

Once your request form has been received and reviewed by the PEB a Departmental officer will be in touch to arrange a meeting time.

If the item to be discussed is a co-dependent technology sponsors must first contact the Health Technology Assessment (HTA) team (hta@health.gov.au) to arrange a joint meeting.

Health technologies are co-dependent if their use needs to be combined (either sequentially or simultaneously) to achieve or enhance the intended clinical effect of either technology.  For example, a drug/test combination where a new medicine seeking listing on the PBS may have a related pathology test that helps to determine the population group for that medicine.

Further information about the HTA processes can be found on the Department of Health website.